Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Neoplasms, Experimental | 12 | 2019 | 269 | 2.300 |
Why?
|
Immunotherapy | 11 | 2021 | 627 | 1.730 |
Why?
|
Radiotherapy | 5 | 2020 | 326 | 1.670 |
Why?
|
Neoplasms | 18 | 2023 | 2889 | 1.500 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 3 | 2019 | 123 | 1.190 |
Why?
|
Dendritic Cells | 15 | 2018 | 424 | 1.190 |
Why?
|
Tumor Escape | 5 | 2017 | 49 | 1.160 |
Why?
|
Adoptive Transfer | 3 | 2017 | 168 | 1.150 |
Why?
|
Immunotherapy, Adoptive | 7 | 2015 | 170 | 1.100 |
Why?
|
CD8-Positive T-Lymphocytes | 8 | 2017 | 556 | 1.090 |
Why?
|
Myeloid Cells | 2 | 2015 | 97 | 0.970 |
Why?
|
Interferon-gamma | 8 | 2019 | 444 | 0.920 |
Why?
|
Genetic Therapy | 8 | 2015 | 342 | 0.910 |
Why?
|
Radioimmunotherapy | 1 | 2020 | 25 | 0.730 |
Why?
|
Antibodies, Monoclonal | 9 | 2009 | 1376 | 0.700 |
Why?
|
Tumor Microenvironment | 4 | 2023 | 415 | 0.670 |
Why?
|
Killer Cells, Natural | 7 | 2012 | 267 | 0.630 |
Why?
|
Vascular Remodeling | 1 | 2017 | 21 | 0.610 |
Why?
|
Interleukin-15 | 4 | 2012 | 72 | 0.600 |
Why?
|
Blood Vessels | 1 | 2017 | 94 | 0.590 |
Why?
|
Animals | 42 | 2023 | 26518 | 0.590 |
Why?
|
Tumor Necrosis Factor Receptor Superfamily, Member 9 | 6 | 2009 | 15 | 0.590 |
Why?
|
Cell Line, Tumor | 14 | 2021 | 2421 | 0.580 |
Why?
|
CD4-Positive T-Lymphocytes | 3 | 2017 | 425 | 0.580 |
Why?
|
T-Lymphocytes | 7 | 2015 | 1195 | 0.580 |
Why?
|
Cell Hypoxia | 1 | 2017 | 164 | 0.570 |
Why?
|
Mice, Inbred C57BL | 19 | 2019 | 3087 | 0.560 |
Why?
|
Cell Communication | 2 | 2015 | 194 | 0.560 |
Why?
|
Cancer-Associated Fibroblasts | 1 | 2016 | 36 | 0.560 |
Why?
|
B7-H1 Antigen | 2 | 2017 | 250 | 0.540 |
Why?
|
Ischemia | 1 | 2017 | 242 | 0.520 |
Why?
|
Mice | 30 | 2023 | 11313 | 0.510 |
Why?
|
Chemoradiotherapy | 1 | 2016 | 301 | 0.460 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2017 | 589 | 0.460 |
Why?
|
Receptors, Nerve Growth Factor | 4 | 2006 | 11 | 0.450 |
Why?
|
Receptors, Tumor Necrosis Factor | 4 | 2006 | 88 | 0.440 |
Why?
|
Mice, Knockout | 6 | 2019 | 1918 | 0.430 |
Why?
|
T-Lymphocyte Subsets | 1 | 2013 | 272 | 0.410 |
Why?
|
Colonic Neoplasms | 5 | 2018 | 554 | 0.410 |
Why?
|
Interleukin-12 | 5 | 2005 | 108 | 0.380 |
Why?
|
Macrophages | 1 | 2013 | 554 | 0.380 |
Why?
|
Antigens, Neoplasm | 5 | 2017 | 324 | 0.360 |
Why?
|
Liver | 3 | 2012 | 1229 | 0.360 |
Why?
|
Antigens, CD | 9 | 2008 | 457 | 0.350 |
Why?
|
Plasmacytoma | 1 | 2008 | 34 | 0.340 |
Why?
|
Combined Modality Therapy | 5 | 2020 | 1680 | 0.340 |
Why?
|
Tumor Burden | 3 | 2017 | 288 | 0.320 |
Why?
|
Adjuvants, Immunologic | 1 | 2008 | 166 | 0.310 |
Why?
|
NF-kappa B | 2 | 2021 | 442 | 0.290 |
Why?
|
Mice, Transgenic | 9 | 2019 | 1537 | 0.280 |
Why?
|
T-Lymphocytes, Cytotoxic | 5 | 2012 | 314 | 0.260 |
Why?
|
Multiple Myeloma | 1 | 2008 | 307 | 0.250 |
Why?
|
Membrane Proteins | 4 | 2023 | 1194 | 0.250 |
Why?
|
Isoantigens | 1 | 2004 | 66 | 0.240 |
Why?
|
Green Fluorescent Proteins | 4 | 2016 | 305 | 0.240 |
Why?
|
Cell Movement | 3 | 2019 | 756 | 0.240 |
Why?
|
Immunologic Memory | 3 | 2013 | 152 | 0.230 |
Why?
|
Cytotoxicity, Immunologic | 3 | 2016 | 213 | 0.230 |
Why?
|
Cancer Vaccines | 3 | 2013 | 156 | 0.230 |
Why?
|
Lymphocyte Count | 2 | 2017 | 94 | 0.230 |
Why?
|
Environment | 1 | 2005 | 219 | 0.230 |
Why?
|
Lymphocyte Activation | 3 | 2016 | 727 | 0.220 |
Why?
|
Adenoviridae | 6 | 2006 | 345 | 0.220 |
Why?
|
Spleen | 4 | 2012 | 430 | 0.220 |
Why?
|
Gene Expression Profiling | 2 | 2019 | 1381 | 0.210 |
Why?
|
Metal-Organic Frameworks | 1 | 2021 | 13 | 0.210 |
Why?
|
Radiation Tolerance | 2 | 2019 | 168 | 0.210 |
Why?
|
Transforming Growth Factor beta | 1 | 2023 | 298 | 0.210 |
Why?
|
Erythroid Precursor Cells | 1 | 2021 | 32 | 0.200 |
Why?
|
CDC2 Protein Kinase | 1 | 2021 | 45 | 0.200 |
Why?
|
Mice, Inbred BALB C | 7 | 2009 | 1047 | 0.190 |
Why?
|
Cytoreduction Surgical Procedures | 1 | 2020 | 71 | 0.190 |
Why?
|
CTLA-4 Antigen | 5 | 2008 | 135 | 0.190 |
Why?
|
Neutrophils | 1 | 2021 | 306 | 0.180 |
Why?
|
Disease Models, Animal | 4 | 2018 | 2227 | 0.180 |
Why?
|
Receptors, Chemokine | 2 | 2013 | 31 | 0.180 |
Why?
|
Pancreatic Neoplasms | 3 | 2016 | 645 | 0.180 |
Why?
|
Humans | 28 | 2023 | 86281 | 0.180 |
Why?
|
Immunization | 4 | 2013 | 158 | 0.180 |
Why?
|
Glioblastoma | 1 | 2021 | 254 | 0.170 |
Why?
|
Transfection | 5 | 2008 | 895 | 0.170 |
Why?
|
Receptors, Interferon | 2 | 2017 | 31 | 0.170 |
Why?
|
Receptors, Pattern Recognition | 1 | 2018 | 19 | 0.170 |
Why?
|
Mice, Inbred C3H | 3 | 2013 | 370 | 0.160 |
Why?
|
Gene Transfer Techniques | 2 | 2012 | 152 | 0.160 |
Why?
|
Cell Survival | 2 | 2019 | 966 | 0.160 |
Why?
|
Antineoplastic Agents, Immunological | 2 | 2018 | 185 | 0.160 |
Why?
|
Flow Cytometry | 6 | 2012 | 679 | 0.160 |
Why?
|
Immunity, Innate | 2 | 2018 | 405 | 0.160 |
Why?
|
Antigens, Differentiation | 4 | 2006 | 141 | 0.150 |
Why?
|
Intravital Microscopy | 1 | 2017 | 11 | 0.150 |
Why?
|
Melanoma, Experimental | 2 | 2018 | 103 | 0.150 |
Why?
|
Necrosis | 1 | 2017 | 204 | 0.150 |
Why?
|
Antigen Presentation | 4 | 2021 | 209 | 0.140 |
Why?
|
Substrate Specificity | 1 | 2017 | 347 | 0.140 |
Why?
|
Stromal Cells | 1 | 2017 | 142 | 0.140 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2017 | 158 | 0.140 |
Why?
|
Collagen Type I | 1 | 2016 | 62 | 0.140 |
Why?
|
eIF-2 Kinase | 1 | 2015 | 46 | 0.140 |
Why?
|
Brain Neoplasms | 1 | 2021 | 763 | 0.130 |
Why?
|
Immunomodulation | 1 | 2015 | 55 | 0.130 |
Why?
|
Nucleotidyltransferases | 1 | 2014 | 29 | 0.130 |
Why?
|
Recombinant Proteins | 4 | 2012 | 1014 | 0.130 |
Why?
|
Wound Healing | 1 | 2017 | 342 | 0.130 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2021 | 1196 | 0.130 |
Why?
|
Radiosurgery | 1 | 2018 | 272 | 0.130 |
Why?
|
Vaccination | 1 | 2016 | 253 | 0.120 |
Why?
|
Cytokines | 2 | 2017 | 775 | 0.120 |
Why?
|
Skin Window Technique | 1 | 2013 | 3 | 0.120 |
Why?
|
Melanoma | 1 | 2018 | 454 | 0.120 |
Why?
|
Endothelial Cells | 1 | 2017 | 427 | 0.120 |
Why?
|
Models, Immunological | 2 | 2005 | 80 | 0.120 |
Why?
|
CD11b Antigen | 1 | 2013 | 36 | 0.120 |
Why?
|
Bacterial Vaccines | 1 | 2013 | 41 | 0.120 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2015 | 371 | 0.120 |
Why?
|
Models, Biological | 2 | 2013 | 1748 | 0.110 |
Why?
|
Immunity, Cellular | 3 | 2018 | 177 | 0.110 |
Why?
|
Actins | 1 | 2016 | 448 | 0.110 |
Why?
|
Cell Adhesion Molecules | 2 | 2003 | 163 | 0.110 |
Why?
|
DNA | 2 | 2018 | 1293 | 0.110 |
Why?
|
Lipoproteins, HDL | 1 | 2012 | 96 | 0.110 |
Why?
|
Antibodies, Monoclonal, Humanized | 1 | 2018 | 929 | 0.110 |
Why?
|
Programmed Cell Death 1 Receptor | 1 | 2013 | 159 | 0.110 |
Why?
|
Cell Proliferation | 3 | 2018 | 1571 | 0.100 |
Why?
|
Neovascularization, Pathologic | 1 | 2013 | 352 | 0.100 |
Why?
|
CD40 Antigens | 2 | 2008 | 43 | 0.100 |
Why?
|
Receptors, Immunologic | 2 | 2007 | 135 | 0.090 |
Why?
|
Survival Analysis | 2 | 2016 | 1536 | 0.090 |
Why?
|
Homeodomain Proteins | 1 | 2013 | 535 | 0.090 |
Why?
|
Leukocyte Common Antigens | 1 | 2009 | 46 | 0.090 |
Why?
|
Treatment Outcome | 3 | 2020 | 7949 | 0.090 |
Why?
|
Cross-Priming | 3 | 2015 | 48 | 0.090 |
Why?
|
Neoplasm Metastasis | 3 | 2020 | 1056 | 0.080 |
Why?
|
Female | 11 | 2018 | 44405 | 0.080 |
Why?
|
Genes, RAG-1 | 1 | 2008 | 13 | 0.080 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2008 | 877 | 0.080 |
Why?
|
Injections, Intravenous | 1 | 2008 | 243 | 0.080 |
Why?
|
DNA-Binding Proteins | 1 | 2013 | 1208 | 0.080 |
Why?
|
Parkinsonian Disorders | 1 | 2007 | 21 | 0.080 |
Why?
|
Adaptive Immunity | 2 | 2021 | 164 | 0.070 |
Why?
|
Microglia | 1 | 2007 | 102 | 0.070 |
Why?
|
Radiation, Ionizing | 2 | 2018 | 121 | 0.070 |
Why?
|
Bone Marrow Cells | 1 | 2007 | 253 | 0.070 |
Why?
|
Peritoneal Neoplasms | 1 | 2007 | 175 | 0.070 |
Why?
|
B7-1 Antigen | 1 | 2006 | 75 | 0.070 |
Why?
|
Transgenes | 1 | 2006 | 180 | 0.070 |
Why?
|
Viral Hepatitis Vaccines | 1 | 2005 | 5 | 0.070 |
Why?
|
Interleukin-8 | 1 | 2005 | 85 | 0.070 |
Why?
|
Interferon Type I | 1 | 2006 | 175 | 0.070 |
Why?
|
Virus Diseases | 1 | 2006 | 96 | 0.070 |
Why?
|
Immune Tolerance | 2 | 2005 | 337 | 0.070 |
Why?
|
Genetic Engineering | 1 | 2005 | 114 | 0.060 |
Why?
|
Hepacivirus | 1 | 2005 | 159 | 0.060 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2004 | 106 | 0.060 |
Why?
|
Viral Core Proteins | 1 | 2003 | 27 | 0.060 |
Why?
|
Viral Envelope Proteins | 1 | 2003 | 94 | 0.060 |
Why?
|
Tissue Engineering | 1 | 2004 | 181 | 0.060 |
Why?
|
Nerve Tissue Proteins | 2 | 2021 | 503 | 0.050 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2002 | 70 | 0.050 |
Why?
|
Liver Neoplasms | 2 | 2006 | 731 | 0.050 |
Why?
|
Mastitis, Bovine | 1 | 2001 | 1 | 0.050 |
Why?
|
Apoptosis | 2 | 2006 | 1678 | 0.050 |
Why?
|
Macrophage-1 Antigen | 1 | 2001 | 17 | 0.050 |
Why?
|
CD3 Complex | 1 | 2001 | 135 | 0.050 |
Why?
|
Gene Expression | 1 | 2006 | 1281 | 0.050 |
Why?
|
RNA-Binding Proteins | 1 | 2023 | 244 | 0.050 |
Why?
|
Ovalbumin | 2 | 2013 | 109 | 0.050 |
Why?
|
Mammary Glands, Animal | 1 | 2001 | 78 | 0.050 |
Why?
|
Male | 5 | 2018 | 40860 | 0.050 |
Why?
|
Base Sequence | 2 | 2021 | 2329 | 0.050 |
Why?
|
Tumor Cells, Cultured | 3 | 2011 | 1040 | 0.050 |
Why?
|
Carcinoma | 1 | 2004 | 434 | 0.050 |
Why?
|
Immunoconjugates | 1 | 2002 | 106 | 0.050 |
Why?
|
Antigen-Presenting Cells | 1 | 2021 | 139 | 0.050 |
Why?
|
Cell Differentiation | 1 | 2007 | 1456 | 0.050 |
Why?
|
Interferon-beta | 2 | 2014 | 125 | 0.050 |
Why?
|
Colorectal Neoplasms | 1 | 2007 | 924 | 0.050 |
Why?
|
Antineoplastic Agents | 2 | 2014 | 2351 | 0.040 |
Why?
|
Peptide Fragments | 2 | 2013 | 460 | 0.040 |
Why?
|
Chromosomal Instability | 1 | 2018 | 19 | 0.040 |
Why?
|
Transcription Factor RelA | 1 | 2018 | 49 | 0.040 |
Why?
|
Adenocarcinoma | 1 | 2006 | 1160 | 0.040 |
Why?
|
Binding Sites | 1 | 2021 | 1098 | 0.040 |
Why?
|
Response Evaluation Criteria in Solid Tumors | 1 | 2018 | 56 | 0.040 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2018 | 188 | 0.040 |
Why?
|
Receptors, Natural Killer Cell | 2 | 2007 | 20 | 0.040 |
Why?
|
Promoter Regions, Genetic | 1 | 2021 | 937 | 0.040 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2012 | 376 | 0.040 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2018 | 458 | 0.040 |
Why?
|
Radiotherapy Dosage | 1 | 2018 | 468 | 0.040 |
Why?
|
Homeostasis | 1 | 2018 | 408 | 0.040 |
Why?
|
Chemokines | 1 | 2016 | 72 | 0.040 |
Why?
|
Bystander Effect | 1 | 2015 | 12 | 0.030 |
Why?
|
Signal Transduction | 2 | 2018 | 3233 | 0.030 |
Why?
|
Transcription Factors | 1 | 2023 | 1555 | 0.030 |
Why?
|
Bone Marrow Transplantation | 2 | 2007 | 285 | 0.030 |
Why?
|
Cells, Cultured | 2 | 2014 | 2810 | 0.030 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2015 | 89 | 0.030 |
Why?
|
Xanthones | 1 | 2014 | 11 | 0.030 |
Why?
|
Nucleotides, Cyclic | 1 | 2014 | 10 | 0.030 |
Why?
|
Receptor, Interferon alpha-beta | 1 | 2014 | 20 | 0.030 |
Why?
|
Point Mutation | 1 | 2015 | 246 | 0.030 |
Why?
|
Disease Progression | 2 | 2011 | 1531 | 0.030 |
Why?
|
Adaptor Proteins, Vesicular Transport | 1 | 2014 | 49 | 0.030 |
Why?
|
Myeloid Differentiation Factor 88 | 1 | 2014 | 47 | 0.030 |
Why?
|
Biopsy | 1 | 2018 | 1160 | 0.030 |
Why?
|
RNA Interference | 1 | 2014 | 368 | 0.030 |
Why?
|
Genetic Vectors | 2 | 2006 | 438 | 0.030 |
Why?
|
Interleukin-15 Receptor alpha Subunit | 1 | 2012 | 6 | 0.030 |
Why?
|
Injections, Subcutaneous | 1 | 2012 | 117 | 0.030 |
Why?
|
Epitopes | 1 | 2013 | 255 | 0.030 |
Why?
|
RNA, Small Interfering | 1 | 2014 | 547 | 0.030 |
Why?
|
Autoimmunity | 2 | 2006 | 160 | 0.030 |
Why?
|
Cell Count | 1 | 2012 | 194 | 0.030 |
Why?
|
Apolipoprotein A-I | 1 | 2012 | 71 | 0.030 |
Why?
|
Inclusion Bodies | 1 | 2012 | 34 | 0.030 |
Why?
|
DNA, Neoplasm | 1 | 2012 | 265 | 0.020 |
Why?
|
Genes, p53 | 1 | 2011 | 109 | 0.020 |
Why?
|
Blotting, Western | 1 | 2012 | 781 | 0.020 |
Why?
|
Protein Structure, Tertiary | 1 | 2012 | 736 | 0.020 |
Why?
|
ATP-Binding Cassette Transporters | 1 | 2011 | 141 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2012 | 927 | 0.020 |
Why?
|
Mice, Nude | 1 | 2011 | 790 | 0.020 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily K | 1 | 2007 | 29 | 0.020 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 1 | 2007 | 32 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2012 | 1752 | 0.020 |
Why?
|
Whole-Body Irradiation | 1 | 2007 | 63 | 0.020 |
Why?
|
Aged, 80 and over | 1 | 2018 | 6481 | 0.020 |
Why?
|
Mesoderm | 1 | 2007 | 107 | 0.020 |
Why?
|
Fluorescent Antibody Technique | 1 | 2007 | 314 | 0.020 |
Why?
|
Time Factors | 2 | 2007 | 5198 | 0.020 |
Why?
|
Thymus Gland | 1 | 2007 | 195 | 0.020 |
Why?
|
Thymidine Kinase | 1 | 2006 | 30 | 0.020 |
Why?
|
Phenotype | 1 | 2012 | 2375 | 0.020 |
Why?
|
Ligands | 1 | 2007 | 433 | 0.020 |
Why?
|
Viral Vaccines | 1 | 2006 | 43 | 0.020 |
Why?
|
Dopamine | 1 | 2007 | 275 | 0.020 |
Why?
|
Aged | 2 | 2018 | 18353 | 0.020 |
Why?
|
Interferon-alpha | 1 | 2006 | 233 | 0.020 |
Why?
|
Gene Silencing | 1 | 2006 | 172 | 0.020 |
Why?
|
Chemotaxis | 1 | 2005 | 72 | 0.020 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2006 | 169 | 0.020 |
Why?
|
Vaccines, Synthetic | 1 | 2005 | 55 | 0.020 |
Why?
|
Injections, Intralesional | 1 | 2004 | 22 | 0.020 |
Why?
|
Leukocytes, Mononuclear | 1 | 2006 | 196 | 0.020 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2006 | 173 | 0.020 |
Why?
|
Lymphopenia | 1 | 2004 | 28 | 0.020 |
Why?
|
HeLa Cells | 1 | 2006 | 498 | 0.020 |
Why?
|
Viral Load | 1 | 2005 | 148 | 0.020 |
Why?
|
Recombinant Fusion Proteins | 1 | 2006 | 555 | 0.020 |
Why?
|
Safety | 1 | 2004 | 152 | 0.020 |
Why?
|
Fever | 1 | 2004 | 125 | 0.020 |
Why?
|
Middle Aged | 2 | 2018 | 24957 | 0.010 |
Why?
|
Receptors, CCR6 | 1 | 2003 | 3 | 0.010 |
Why?
|
Chemokine CCL20 | 1 | 2003 | 3 | 0.010 |
Why?
|
Macrophage Inflammatory Proteins | 1 | 2003 | 9 | 0.010 |
Why?
|
CD40 Ligand | 1 | 2003 | 69 | 0.010 |
Why?
|
Adult | 2 | 2018 | 25577 | 0.010 |
Why?
|
Viral Nonstructural Proteins | 1 | 2003 | 37 | 0.010 |
Why?
|
Chemokines, CC | 1 | 2003 | 34 | 0.010 |
Why?
|
Interleukin-6 | 1 | 2004 | 255 | 0.010 |
Why?
|
Cross-Linking Reagents | 1 | 2003 | 86 | 0.010 |
Why?
|
Transplantation, Homologous | 1 | 2006 | 996 | 0.010 |
Why?
|
Cell Separation | 1 | 2003 | 196 | 0.010 |
Why?
|
Transduction, Genetic | 1 | 2003 | 153 | 0.010 |
Why?
|
Remission Induction | 1 | 2004 | 722 | 0.010 |
Why?
|
Neoplasm Transplantation | 1 | 2003 | 391 | 0.010 |
Why?
|
Hepatitis C | 1 | 2005 | 208 | 0.010 |
Why?
|
Feasibility Studies | 1 | 2004 | 751 | 0.010 |
Why?
|
Cell Death | 1 | 2003 | 256 | 0.010 |
Why?
|
Chronic Disease | 1 | 2006 | 968 | 0.010 |
Why?
|
Receptors, Interleukin-2 | 1 | 2002 | 66 | 0.010 |
Why?
|
Colony Count, Microbial | 1 | 2001 | 46 | 0.010 |
Why?
|
Abatacept | 1 | 2002 | 83 | 0.010 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2006 | 380 | 0.010 |
Why?
|
Lymphocyte Subsets | 1 | 2001 | 64 | 0.010 |
Why?
|
Milk | 1 | 2001 | 53 | 0.010 |
Why?
|
Leukocyte Count | 1 | 2001 | 220 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 2006 | 1135 | 0.010 |
Why?
|
Cattle | 1 | 2001 | 374 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2006 | 3029 | 0.010 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2003 | 689 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2006 | 1168 | 0.010 |
Why?
|
Mutation | 1 | 2011 | 3952 | 0.010 |
Why?
|
Peptides | 1 | 2003 | 639 | 0.010 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2003 | 683 | 0.010 |
Why?
|
Staphylococcus aureus | 1 | 2001 | 263 | 0.010 |
Why?
|
Cohort Studies | 1 | 2004 | 2759 | 0.010 |
Why?
|
Brain | 1 | 2007 | 2211 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2001 | 1987 | 0.010 |
Why?
|